GBS complement inhibitor heads to FDA with striking Phase 3 data; approval verdict determines whether Annexon becomes a commercial company

Annexon is a clinical-stage company developing tanruprubart, a targeted therapy for Guillain-Barré syndrome, a rare nerve disorder that currently has no approved treatment for this condition.

Tanruprubart, an anti-C1q antibody for Guillain-Barré syndrome, an acute paralytic nerve disorder with no approved targeted therapy, showed ~90% of patients improving by week 1 in a placebo-controlled Phase 3. The thesis resolves on whether FDA accepts the BLA and grants approval, with EMA review running in parallel. The chief approval-path risk is that the generalizability package, the stated focus of pre-BLA FDA discussions, must satisfy regulators before any commercial milestone triggers the $100M Oxford credit tranche.